FY2026 · ended Apr 30, 2026 · Revenue $59.42M, +4.4% YoY · Filed Jul 27, 2026
Champions Oncology, Inc. (CSBR) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2026, which ended Apr 30, 2026, it reported revenue of $59.4 million and a net loss of $1.2 million. Free cash flow was -$5.0 million. As of Jul 31, 2026 it held $4.4 million in cash and investments and $10.3 million in total debt.
Revenue (TTM)
$60.66M
+6.7% vs year-ago TTM
Net income (TTM)
$-1.14M
-138.8% vs year-ago TTM
Operating cash flow (TTM)
$-5.56M
-172.5% vs year-ago TTM
Free cash flow (TTM)
$-6.14M
-184.8% vs year-ago TTM
EPS
$-0.08
-124.2% vs prior year
Dividend per share
None
Shares outstanding
13.89M
+0.8% vs prior year
Net cash
$-5.96M
as of Jul 31, 2026
Operating margin
-1.7%
FY 2027
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CSBR (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- DE
- Headquarters
- Baltimore, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 771856
- Former names
- CHAMPIONS BIOTECHNOLOGY, INC. (until Mar 30, 2011); CHAMPIONS SPORTS INC (until Feb 16, 2007)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Apr 30, 2026 |
FY 2025 Apr 30, 2025 |
FY 2024 Apr 30, 2024 |
FY 2023 Apr 30, 2023 |
FY 2022 Apr 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $59.4M | $56.9M | $50.2M | $53.9M | $49.1M |
| Operating income | -$1.1M | $4.6M | -$7.4M | -$5.3M | $607,000 |
| Net income | -$1.2M | $4.7M | -$7.3M | -$5.3M | $548,000 |
| Diluted EPS | -$0.08 | $0.33 | -$0.54 | -$0.39 | $0.04 |
| Operating cash flow | -$4.5M | $7.4M | -$6.1M | $4.0M | $6.5M |
| Free cash flow | -$5.0M | $7.0M | -$7.0M | $1.1M | $4.1M |
| Total assets | $27.0M | $32.3M | $26.1M | $34.3M | $35.4M |
| Total liabilities | $22.9M | $28.6M | $28.0M | $29.7M | $26.3M |
| Stockholders' equity | $3.9M | $3.8M | -$1.9M | $4.6M | $9.1M |
| Cash and investments | $4.9M | $9.8M | $2.6M | $10.1M | $9.0M |
| Total debt | $4.6M | $6.3M | $7.8M | $8.7M | $9.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 16, 2026 | Oct 14, 2026 |
| 10-Q | Quarterly report | Sep 11, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 10, 2026 | Sep 10, 2026 |
| 10-K | Annual report | Jul 27, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 27, 2026 | Jul 27, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 30, 2026 | Mar 24, 2026 |
All 655 Champions Oncology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.